Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
Susceptibility tensor imaging (STI) of the brain.
Hyperforin-loaded gold nanoparticle alleviates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells.
The possible effects of the solar and geomagnetic activity on multiple sclerosis.
Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1.
Reassessing the risk of natalizumab-associated PML.
Alkali metals levels in the human brain tissue: Anatomical region differences and age-related changes.
Novantrone
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.
Myelinating satellite oligodendrocytes are integrated in a glial syncytium constraining neuronal high-frequency activity.
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression.
Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.
Women's Issues in Multiple Sclerosis.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
[Immunomodulation and neuroprotection in optic neuritis].
The use of hematopoietic stem cells in autoimmune diseases.
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon.
Effects of dimethyl fumarate on lymphocyte subsets.
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

Pages